KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for CRISPR Therapeutics AG (CRSP) over the last 7 years, with Q3 2025 value amounting to $57.1 million.

  • CRISPR Therapeutics AG's Other Operating Expenses rose 41210.44% to $57.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $256.0 million, marking a year-over-year increase of 9656.81%. This contributed to the annual value of $110.2 million for FY2024, which is 1535.51% down from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported Other Operating Expenses of $57.1 million as of Q3 2025, which was up 41210.44% from $141.4 million recorded in Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Other Operating Expenses peaked at $141.4 million during Q2 2025, and registered a low of $6.8 million during Q4 2022.
  • In the last 5 years, CRISPR Therapeutics AG's Other Operating Expenses had a median value of $32.9 million in 2021 and averaged $39.3 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first crashed by 7856.02% in 2022, then skyrocketed by 41210.44% in 2025.
  • CRISPR Therapeutics AG's Other Operating Expenses (Quarter) stood at $31.8 million in 2021, then crashed by 78.56% to $6.8 million in 2022, then surged by 193.13% to $20.0 million in 2023, then crashed by 44.24% to $11.2 million in 2024, then skyrocketed by 412.1% to $57.1 million in 2025.
  • Its last three reported values are $57.1 million in Q3 2025, $141.4 million for Q2 2025, and $57.5 million during Q1 2025.